• / Free eNewsletters & Magazine
  • / My Account
Home>Companies>Biogen Idec

Biogen Idec

  1. All
  2. Morningstar Articles
  3. Videos
  4. 3rd Party
  5. Investing
  1. Detailed Results from Biogen Idec and AbbVie’s Pivotal Phase 3 Decide Study Further Define the Efficacy and Safety Profile of ZINBRYTA™ (Daclizumab High-Yield Process)

    Detailed Results from Biogen Idec and AbbVie’s Pivotal Phase 3 Decide Study Further Define the Efficacy and Safety Profile of ZINBRYTA™ (Daclizumab High-Yield Process)

  2. UPDATE: 14 stocks loved by top-performing fund -2-

    UPDATE: 14 stocks loved by top-performing fund -2-

  3. UPDATE: 14 stocks loved by top-performing fund managers

    UPDATE: 14 stocks loved by top-performing fund managers

  4. UPDATE: 14 stocks loved by top-performing fund -3-

    UPDATE: 14 stocks loved by top-performing fund -3-

  5. Research and Markets: Global Multiple Sclerosis Drugs Market 2014-2018 Featuring Bayer, Biogen Idec , Merck Serono, Novartis & Teva Pharmaceutical

    Research and Markets: Global Multiple Sclerosis Drugs Market 2014-2018 Featuring Bayer, Biogen Idec , Merck Serono, Novartis & Teva Pharmaceutical

  6. FDA accepts Tuzistra™ XR (CCP-01) NDA for full review

    FDA accepts Tuzistra™ XR (CCP-01) NDA for full review

  7. BioPharm America™ 2014 Leads off With Fierce 15 Announcement and Keynote Address Featuring Chief Scientific Officer From Sanofi

    BioPharm America™ 2014 Leads off With Fierce 15 Announcement and Keynote Address Featuring Chief Scientific Officer From Sanofi

  8. UPDATE: Biotech companies take the real ice bucket challenge

    UPDATE: Biotech companies take the real ice bucket challenge

1234
Upcoming Events
Conferences
Webinars

©2014 Morningstar Advisor. All right reserved.